tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Inspira Technologies Secures Pathway for ART100’s National and Global Expansion

Story Highlights
Inspira Technologies Secures Pathway for ART100’s National and Global Expansion

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from Inspira Technologies Oxy BHN ( (IINN) ).

On July 10, 2025, Inspira Technologies announced that it has achieved all key objectives in talks with a government health authority outside the U.S., paving the way for national adoption of its ART100 system and setting the stage for global expansion. This development is expected to enhance the company’s operations by accelerating the integration of the ART100 into national emergency infrastructure and establishing a global distribution and manufacturing hub, significantly boosting the value of an existing $22.5 million purchase order.

The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.

Spark’s Take on IINN Stock

According to Spark, TipRanks’ AI Analyst, IINN is a Underperform.

The overall stock score reflects significant financial instability, as indicated by ongoing losses and reliance on external funding. The technical analysis shows bearish sentiment, with the stock under pressure. Valuation is challenging due to negative earnings and lack of dividend yield, making the stock less appealing to investors.

To see Spark’s full report on IINN stock, click here.

More about Inspira Technologies Oxy BHN

Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. Their products include the FDA-cleared INSPIRA ART100 system, used for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., and the HYLA blood sensor platform for continuous, non-invasive monitoring. The company is positioned within the life-support and MedTech landscape, focusing on strategic partnerships and industry trends.

Average Trading Volume: 898,958

Technical Sentiment Signal: Buy

Current Market Cap: $38.17M

For detailed information about IINN stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1